Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2017, Article ID 6527306, 9 pages
https://doi.org/10.1155/2017/6527306
Research Article

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients

1Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
2Transplant Immunology & Immunogenetics, Oxford Transplant Centre, Churchill Hospital, Oxford, UK
3Department of Clinical Haematology, Churchill Hospital, Oxford, UK

Correspondence should be addressed to Karen Pulford; ku.ca.xo.slcdn@droflup.nerak

Received 30 July 2017; Accepted 12 September 2017; Published 24 October 2017

Academic Editor: Shaji Kumar

Copyright © 2017 Kamel Ait-Tahar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Stein, J. Chan, R. Warnke et al., “Diffuse large B-cell lymphoma, not otherwise specified, WHO Classification of tumours of haematopoietic and lymphoid tissues,” in International Agency for Research on Cancer, pp. 233–237, Lyon, France, 2008.
  2. B. Coiffier, “Rituximab therapy in malignant lymphoma,” Oncogene, vol. 26, no. 25, pp. 3603–3613, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. S. M. Ansell, A. M. Lesokhin, I. Borrello et al., “PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma,” The New England Journal of Medicine, vol. 372, no. 4, pp. 311–319, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. A. L. Garfall, M. V. Maus, W.-T. Hwang et al., “Chimeric antigen receptor T cells against CD19 for multiple myeloma,” The New England Journal of Medicine, vol. 373, no. 11, pp. 1040–1047, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Atanackovic, J. Arfsten, Y. Cao et al., “Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation,” Blood, vol. 109, no. 3, pp. 1103–1112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. D. L. Porter and J. H. Antin, “Donor leukocyte infusions in myeloid malignancies: new strategies,” Best Practice & Research Clinical Haematology, vol. 19, no. 4, pp. 737–755, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. R. J. Inaoka, A. A. Jungbluth, S. Gnjatic et al., “Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients,” Cancer Immunology, Immunotherapy, vol. 61, no. 12, pp. 2207–2214, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. R. J. Inaoka, A. A. Jungbluth, O. C. G. Baiocchi et al., “An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients,” BMC Cancer, vol. 11, article no. 416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Atanackovic, T. Luetkens, B. Kloth et al., “Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia,” American Journal of Hematology, vol. 86, no. 11, pp. 918–922, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Srivastava, B. E. Paluch, J. Matsuzaki et al., “Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts,” Leukemia Research, vol. 38, no. 11, pp. 1332–1341, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Pellat-Deceunynck, M.-P. Mellerin, N. Labarrière et al., “The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells,” European Journal of Immunology, vol. 30, no. 3, pp. 803–809, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. S. H. Lim, Z. Wang, M. Chiriva-Internati, and Y. Xue, “Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma,” Blood, vol. 97, no. 5, pp. 1508–1510, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. O. Goodyear, K. Piper, N. Khan et al., “CD8+T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden,” Blood, vol. 106, no. 13, pp. 4217–4224, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. F. De Carvalho, V. L. F. Alves, W. M. T. Braga, C. V. Xavier Jr., and G. W. B. Colleoni, “MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy,” Cancer Immunology, Immunotherapy, vol. 62, no. 1, pp. 191–195, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. B. J. Taylor, T. Reiman, J. A. Pittman et al., “SSX cancer testis antigens are expressed in most multiple myeloma patients: Co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs,” Journal of Immunotherapy, vol. 28, no. 6, pp. 564–575, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. M. F. Gjerstorff, M. H. Andersen, and H. J. Ditzel, “Oncogenic cancer/testis antigens: prime candidates for immunotherapy,” Oncotarget , vol. 6, no. 18, pp. 15772–15787, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. O. L. Caballero and Y.-T. Chen, “Cancer/testis (CT) antigens: Potential targets for immunotherapy,” Cancer Science, vol. 100, no. 11, pp. 2014–2021, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. V. I. Seledtsov, A. G. Goncharov, and G. V. Seledtsova, “Clinically feasible approaches to potentiating cancer cell-based immunotherapies,” Human Vaccines & Immunotherapeutics, vol. 11, no. 4, pp. 851–869, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. S. D. Xiang, Q. Gao, K. L. Wilson, A. Heyerick, and M. Plebanski, “Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine,” Vaccine, vol. 33, no. 44, pp. 5950–5959, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. J.-X. Song, W.-L. Cao, F.-Q. Li, L.-N. Shi, and X. Jia, “Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells,” Medical Oncology, vol. 29, no. 4, pp. 2923–2931, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. J. M. Straughn Jr., D. R. Shaw, A. Guerrero et al., “Expression of sperm protein 17 (Sp17) in ovarian cancer,” International Journal of Cancer, vol. 108, no. 6, pp. 805–811, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Mirandola, J. A. Figueroa, T. T. Phan et al., “Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets,” Oncotarget , vol. 6, no. 5, pp. 2812–2826, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Chiriva-Internati, Z. Wang, E. Salati, D. Wroblewski, and S. H. Lim, “Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: Implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma,” Scandinavian Journal of Immunology, vol. 56, no. 4, pp. 429–433, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Chiriva-Internati, Z. Wang, S. Pochopien, E. Salati, and S. H. Lim, “Identification of a sperm protein 17 CTL epitope restricted by HLA-A1,” International Journal of Cancer, vol. 107, no. 5, pp. 863–865, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Chiriva-Internati, Z. Wang, Y. Xue, K. Bumm, A. B. Hahn, and S. H. Lim, “Sperm protein 17 (Sp17) in multiple myeloma: Opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk,” European Journal of Immunology, vol. 31, no. 8, pp. 2277–2283, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. H. M. Lacy and R. D. Sanderson, “Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesion,” Blood, vol. 98, no. 7, pp. 2160–2165, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. A. P. Liggins, S. H. Lim, E. J. Soilleux, K. Pulford, and A. H. Banham, “A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.,” Cancer immunity : a journal of the Academy of Cancer Immunology, vol. 10, p. 8, 2010. View at Google Scholar · View at Scopus
  28. F. Arnaboldi, A. Menon, E. Menegola et al., “Sperm Protein17 is an oncofetal antigen: A lesson from a murine model,” International Reviews of Immunology, vol. 33, no. 5, pp. 367–374, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Ait-Tahar, A. P. Liggins, G. P. Collins et al., “Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma,” British Journal of Haematology, vol. 146, no. 4, pp. 396–407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Ait-Tahar, A. P. Liggins, G. P. Collins et al., “CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma,” Haematologica, vol. 96, no. 1, pp. 78–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Bunce, C. M. O'Neill, M. C. N. M. Barnardo et al., “Phototyping: comprehensive DNA typing for HLA‐A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence‐specific primers (PCR‐SSP),” Tissue Antigens, vol. 46, no. 5, pp. 355–367, 1995. View at Publisher · View at Google Scholar · View at Scopus
  32. C. P. Hans, D. D. Weisenburger, T. C. Greiner et al., “Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray,” Blood, vol. 103, no. 1, pp. 275–282, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Ait-Tahar, V. Cerundolo, A. H. Banham et al., “B and CTL responses to the ALK protein in patients with ALK-positive ALCL,” International Journal of Cancer, vol. 118, no. 3, pp. 688–695, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Grizzi, L. Mirandola, D. Qehajaj, E. Cobos, J. A. Figueroa, and M. Chiriva-Internati, “Cancer-testis antigens and immunotherapy in the light of cancer complexity,” International Reviews of Immunology, vol. 34, no. 2, pp. 143–153, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Huang, K.-D. Preuss, X. Xie, E. Regitz, and M. Pfreundschuh, “Analysis of the antibody repertoire of lymphoma patients,” Cancer Immunology, Immunotherapy, vol. 51, no. 11-12, pp. 655–662, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. X. Xie, H. H. Wacker, S. Huang et al., “Differential expression of cancer testis genes in histological subtypes of non-Hodgkin's lymphomas,” Clinical Cancer Research, vol. 9, no. 1, pp. 167–173, 2003. View at Google Scholar
  37. M. Chiriva-Internati, J. A. Weidanz, Y. Yu et al., “Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer,” Journal of Immunotherapy, vol. 31, no. 8, pp. 693–703, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Chiriva-Internati, Y. Yu, L. Mirandola et al., “Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer,” PLoS ONE, vol. 5, no. 5, Article ID e10471, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. S. D. Xiang, Q. Gao, K. L. Wilson, A. Heyerick, and M. Plebanski, “A nanoparticle based Sp17 peptide vaccine exposes new immuno-dominant and species cross-reactive B cell epitopes,” Vaccines, vol. 3, no. 4, pp. 875–893, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Van Rhee, S. M. Szmania, F. Zhan et al., “NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses,” Blood, vol. 105, no. 10, pp. 3939–3944, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Inokuma, C. Dela Rosa, C. Schmitt et al., “Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature,” The Journal of Immunology, vol. 179, no. 4, pp. 2627–2633, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Passoni, A. Scardino, C. Bertazzoli et al., “ALK as a novel lymphoma-associated tumor antigen: Identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes,” Blood, vol. 99, no. 6, pp. 2100–2106, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Baumgaertner, N. Rufer, E. Devevre et al., “Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens,” Cancer Research, vol. 66, no. 4, pp. 1912–1916, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. N. M. Provine, R. A. Larocca, M. Aid et al., “Immediate dysfunction of vaccine-elicited CD8+ T cells primed in the absence of CD4+ T cells,” The Journal of Immunology, vol. 197, no. 5, pp. 1809–1822, 2016. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Ostrand-Rosenberg, “CD4+ T lymphocytes: A critical component of antitumor immunity,” Cancer Investigation, vol. 23, no. 5, pp. 413–419, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Zeng, “MHC class II-restricted tumor antigens recognized by CD4+ T cells: New strategies for cancer vaccine design,” Journal of Immunotherapy, vol. 24, no. 3, pp. 195–204, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Atanackovic, I. Blum, Y. Cao et al., “Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma,” Cancer Biology & Therapy, vol. 5, no. 9, pp. 1218–1225, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Condomines, D. Hose, P. Raynaud et al., “Cancer/testis genes in multiple myeloma: Expression patterns and prognosis value determined by microarray analysis,” The Journal of Immunology, vol. 178, no. 5, pp. 3307–3315, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. M. V. Dhodapkar, K. Osman, J. Teruya-Feldstein et al., “Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease.,” Cancer immunity : a journal of the Academy of Cancer Immunology, vol. 3, p. 9, 2003. View at Google Scholar · View at Scopus